Vital Therapies, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2017. The supplied filing identifies the registrant as Vital Therapies, Inc., not IMMUNIC, INC.; verify that this is the intended filing.
Business context
Vital Therapies is a clinical-stage biotherapeutics company developing ELAD, an extracorporeal cell-based therapy for acute liver failure. It has no approved products and has not generated revenue from its planned principal operations. Its sole product candidate is being evaluated in the Phase 3 VTL-308 trial for severe alcoholic hepatitis.
Financial performance and position
| Metric | Q1 2017 | Q1 2016 / prior date |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $9.628 million | $6.857 million |
| General and administrative expense | $3.059 million | $2.799 million |
| Total operating expenses | $12.687 million | $9.656 million |
| Net loss | $12.602 million | $9.589 million |
| Net loss per share, basic and diluted | $0.39 | $0.31 |
| Operating cash used | $10.910 million | $9.956 million |
| Cash and cash equivalents | $86.636 million | $59.991 million at Dec. 31, 2016 |
| Total assets | $90.947 million | $64.026 million at Dec. 31, 2016 |
| Current liabilities | $6.450 million | $5.480 million at Dec. 31, 2016 |
| Stockholders’ equity | $84.428 million | $58.446 million at Dec. 31, 2016 |
Operating margins are not meaningful given the absence of revenue. No material debt balance is identified in the supplied balance sheet; long-term liabilities were $69,000. Accumulated deficit was $256.5 million at quarter-end.
Material changes and unusual items
- Operating expenses rose 31% year over year. R&D increased 40%, mainly from VTL-308 trial costs, including higher subject, site, manufacturing and consulting expenses; 24 subjects enrolled in the quarter. G&A increased 9%, largely due to stock-based compensation.
- Financing provided $37.826 million in Q1 2017, principally from the March follow-on offering. The company reported gross proceeds of $40.3 million and net proceeds of $37.3 million from the offering.
- Common shares outstanding increased to 42.207 million at March 31 from 32.143 million at year-end, reflecting the offering.
- The company adopted new stock-compensation guidance in Q1, recognizing forfeitures as they occur; adoption included a $50,000 cumulative-effect adjustment to additional paid-in capital and accumulated deficit.
- After quarter-end, in May 2017, the company entered a lease extending its manufacturing and R&D facility lease through June 2022. Pro forma future minimum lease obligations were $3.228 million.
Outlook, commentary and risks
- Management expected top-line VTL-308 data around mid-2018. As of May 8, 2017, 67 subjects were enrolled and 46 sites were open; the trial was intended to enroll at least 150 subjects and continue until 55 events occurred.
- Management estimated that cash of $86.6 million would fund operations through the first quarter of 2019, beyond anticipated trial results, assuming limited BLA-related activity and no significant commercial infrastructure build. This estimate is subject to trial timing, enrollment, spending and financing risks.
- The prior Phase 3 VTI-208 trial failed to meet its primary and secondary endpoints. VTL-308 relies on analyses of VTI-208 data, and the company cautioned that the new trial may fail, regulators may require a confirmatory trial, and approval is uncertain.
- The company expects continued losses and negative operating cash flow for at least several years, has no committed external funding, and may need additional capital. Further equity financing could dilute shareholders; financing may not be available on acceptable terms.
- Key risks include trial enrollment and outcome, regulatory approval, manufacturing and single-source suppliers, product safety, reimbursement and commercialization, and the company’s dependence on ELAD as its sole product candidate. No material litigation was reported. Management concluded disclosure controls were effective as of March 31, 2017.
Most important facts to verify
- Confirm the issuer identity: the filing names Vital Therapies, Inc., whereas the request names IMMUNIC, INC.
- Check current VTL-308 enrollment, trial status, endpoint assumptions and any subsequent data or regulatory updates.
- Validate the cash runway against actual cash burn, financing needs and the assumptions excluding significant commercial build-out.
- Review dilution from the March 2017 offering, outstanding options and warrants, and remaining shelf/ATM capacity.
- Assess the post-quarter lease commitments and potential additional financing or clinical-trial costs.